Highlights of the Day-Plenary Session<br /><br />June 1, 2014<br /><br />Lowell E. Schnipper, M.D.

Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

Why invite a value discussion?

Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

Clinically Meaningful Outcomes and Implications for Value (Ellis, et al.,J Clin Oncol. 2014 Apr 20;32(12):1277-80

Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

Moving the Discussion to Value it’s far more than Cost

Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

Seeking an Association Between Clinical Benefit, Toxicity and Cost

Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

Phase III ALTTO trial <br />The ALTTO trial did not meet its endpoints (DFS): Neither the L + T vs. T comparison nor the T → L vs. T comparison<br />

Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

<br /> Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials.

Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

E3805<br />CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer

Presented By Lowell Schnipper at 2014 ASCO Annual Meeting